Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-189

Thanks Eire.

I confess I hadn't factored-in 006 at all. I definitely was of the mind that 008 was just too small to confirm DMOAD for labelling purposes, and existed only to enhance the case for DM ahead of partnership discussions (plus help meet TGA criteria to start selling in Aus).

006 clearly has much more scope to take that enhanced understanding of Zilosuls DM properties, and apply greater scientific rigour to confirm DMOAD status for labelling purposes.

Maybe if the 008 results are compelling, there is a discussion to be had about raising capital to take this the whole way through 002 and 006 before partnering for sales and distribution? Surely there would be a bonafide bidding frenzy amongst the pharma giants if PAR found themselves in patent-covered, supply-cornered possession of history's first fully-approved DMOAD for human use?